Nivolumab and Ipilimumab Acting as Tormentors of Advanced Tumors by Unleashing Immune Cells and Associated Collateral Damage

Combining immune checkpoint inhibitors, specifically nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4), holds substantial promise in revolutionizing cancer treatment. This review explores the transformative impact of these combinations, emphasizing their potential for enhancing therapeutic outcomes...

Olles dieđut

Furkejuvvon:
Bibliográfalaš dieđut
Váldodahkkit: Bushra Khan (Dahkki), Rowaid M. Qahwaji (Dahkki), Mashael S. Alfaifi (Dahkki), Mohammad Mobashir (Dahkki)
Materiálatiipa: Girji
Almmustuhtton: MDPI AG, 2024-05-01T00:00:00Z.
Fáttát:
Liŋkkat:Connect to this object online.
Fáddágilkorat: Lasit fáddágilkoriid
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!

Interneahtta

Connect to this object online.

3rd Floor Main Library

oažžasuvvan: 3rd Floor Main Library
Hildobáiki: A1234.567
Njađus 1 Oažžumis